Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

2025 Guidance Reaffirmed, Tariff Impacts Not Included

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.

Pharma product tariffs may be lower for US allies and higher for countries that are not, Bourla opined (Shutterstock)
Key Takeaways
  • Pfizer CEO Albert Bourla told the company’s Q1 2025 earnings call that he remains “cautiously optimistic” about the pharma industry’s position in terms of US tariff, drug pricing and other relevant policies based on ongoing talks with the Trump Administration.

CEO Albert Bourla, during Pfizer’s first quarter 2025 earnings presentation on 29 April, said the company remains in close communication...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Scrip

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.